NRx Pharmaceuticals Amends IND to Advance NRX-101 for Depression Treatment with TMS

NRx Pharmaceuticals has amended its Investigational New Drug filing for NRX-101 to include its use in combination with Transcranial Magnetic Stimulation (TMS) for depression treatment. The update follows evidence showing NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in symptom reduction and clinical response rates exceeding 80%. The Company aims to validate these findings in a well-controlled trial and is in partnership discussions with TMS device manufacturers.